WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc.
Your view on WXIBF
Overview
What the company does, where it operates, and who runs it.
About WuXi Biologics (Cayman) Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Zhisheng Chen
- Headquarters
- No. 108, Meiliang Road, Wuxi, CN
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Zhisheng Chen
- Headquarters
- No. 108, Meiliang Road, Wuxi, CN
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally.
The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities.
WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for WuXi Biologics (Cayman) Inc., and the rating behind it. WXIBF last traded at $5.16, 33.2× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for WuXi Biologics (Cayman) Inc.. Starting points for WuXi Biologics (Cayman) Inc.: P/E 33.2, EPS $1.22, beta 0.47 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for WuXi Biologics (Cayman) Inc.. WuXi Biologics (Cayman) Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for WuXi Biologics (Cayman) Inc.. Trailing twelve-month EPS for WuXi Biologics (Cayman) Inc. stands at $1.22. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for WuXi Biologics (Cayman) Inc.. WuXi Biologics (Cayman) Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
WuXi Biologics (Cayman) Inc. valued side by side against its closest peers. WuXi Biologics (Cayman) Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold WuXi Biologics (Cayman) Inc., and how their positions are changing. At a $21.30B market value, institutional positions materially move WuXi Biologics (Cayman) Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by WuXi Biologics (Cayman) Inc. executives and directors. Shares of WuXi Biologics (Cayman) Inc. have traded between $2.26 and $5.61 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming WuXi Biologics (Cayman) Inc.. WuXi Biologics (Cayman) Inc. is a $21.30B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming WuXi Biologics (Cayman) Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for WuXi Biologics (Cayman) Inc.. Coverage tracks WuXi Biologics (Cayman) Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.